04:09 PM EDT, 10/22/2024 (MT Newswires) -- (Updates with Amgen's ( AMGN ) confirmation in the first and third paragraphs.)

Amgen ( AMGN ) will launch a biosimilar version of Regeneron's (REGN) Eylea after a US appeals court gave a decision in its favor on Tuesday, a spokesperson for Amgen ( AMGN ) told MT Newswires in an email, confirming Reuters' report.

The US Court of Appeals for the Federal Circuit denied Regeneron's request to hold the launch of the biosimilar temporarily during an appeal for a related patent dispute decision in West Virginia, according to the report.

"Following the appeals court decision today, we are launching Pavblu (aflibercept-ayyh)," Amgen's ( AMGN ) spokesperson told MT Newswires. "We look forward to bringing Pavblu to patients as quickly as possible to help expand access to affordable and effective treatment."

Regeneron did not immediately respond to MT Newswires' request for comment.

Price: 320.91, Change: +4.17, Percent Change: +1.32